EMEA-000309-PIP07-21

Key facts

Invented name
RoActemra
Active substance
tocilizumab
Therapeutic area
Infectious diseases
Decision number
P/0333/2021
PIP number
EMEA-000309-PIP07-21
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intravenous use
Contact for public enquiries
Roche Registration GmbH

Tel. +41 616879411
E-mail: info.paediatrics@roche.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating